Unknown OBSERVATIONAL NCT05335577

Role of Urinary Claudin-2, Caveolin-1, and EGF as Diagnostic Biomarkers of Necrotizing Enterocolitis in Preterm Neonates

Concentrations of Urinary Claudin-2, Caveolin-1, and Epidermal Growth Factor (EGF) as the Prototypes of Non-Invasive Biomarkers in the Diagnosis of Necrotizing Enterocolitis in Preterm Neonates

Sponsor: University of Brawijaya

Conditions Enterocolitis, Necrotizing Infant, Premature

Interventions Urinary Caveolin-1 Urinary Claudin-2 Urinary EGF

Updated 4 times since 2022 Last updated: Apr 12, 2022 Started: Mar 17, 2022 Primary completion: May 31, 2022 Completion: Jul 31, 2022

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT05335577, this observational or N/A phase trial focuses on Enterocolitis, Necrotizing and Infant, Premature and remains ongoing. Sponsored by University of Brawijaya, it has been updated 4 times since 2022, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

4 versions recorded

Sep 2024 — Present [monthly]

Unknown
Jul 2024 — Sep 2024 [monthly]

Unknown

Status: Unknown Status → Unknown
May 2024 — Jul 2024 [monthly]

Unknown Status

Status: Recruiting → Unknown Status
May 2022 — May 2024 [monthly]

Recruiting

First recorded

Mar 2022

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

University of Brawijaya

Data source: University of Brawijaya

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Malang, Indonesia